• 41.2% (n=206) of patients with GD had been treated with ERT.
INTRODUCTION
• Gaucher disease (GD) is an autosomal recessive disorder caused by a mutation in the glucocerebrosidase gene. Over 90% of patients have the type 1 non-neuropathic subtype of GD. The incidence of type 1 GD worldwide is low, at 1 in every 100,000 live births, but is exceptionally high among people of Ashkenazi Jewish descent, at 1 in every 850 live births. 1-2 • Patients with this orphan disease exhibit a broad range of symptoms and disease severity that manifest at all ages. GD-related complications and outcomes include hepatomegaly, splenomegaly, bone events and cytopenia.
OBJECTIVES
• To characterise a population-based cohort of patients with GD relative to the general population.
• To describe socio-demographic and clinical differences by disease severity, as defined by the use of enzyme replacement therapy (ERT).
METHODS

Data source
• A cross-sectional study of patients with GD was conducted as of December 31, 2014 using the Clalit Health Services (CHS) electronic health record (EHR) database.
• CHS is the largest health care maintenance organisation in Israel, having >4.2 million insured residents and providing care to >50% of the Israeli population.
Study population
• Included were GD cases as of June 30, 2014, identified using a combination of the following (Figure 1 
Analyses
• Analyses were performed descriptively to characterise the cases' demographics, medical history, clinical characteristics and disease management characteristics.
• Clalit members as of December 31, 2014, excluding patients with GD, were used for the comparison of socio-demographic characteristics.
• Disease prevalence was calculated using the Clalit population and adjusted to the Israel population of 2014. 6 • Chi-square testing was used to assess distributional differences between groups.
• IRB approval was obtained for all analyses.
RESULTS
GD population -general
• Various sources in the EHR data were used to identify the 500 prevalent GD cases ( Figure 1 ). • The prevalence of GD ranged from 5.3 per 100,000 for members ≤34 years of age to 20.2 per 100,000 for those ≥35 years of age. The age-standardised prevalence (according to the Israeli population) is 11.6 per 100,000.
• The majority of GD cases were ≥18 years of age (GD = 91.6% vs Clalit = 68.3%), female (GD = 54.0% vs Clalit = 51.1%), primarily Jewish (GD = 93.6% vs Clalit 73.4%) and of higher socio-economic status relative to the general Clalit population (GD = 34.8% vs Clalit = 19.0%) ( Table 1 ).
• The prevalence of overweight/obesity (among those with documentation) was 51.0% among GD cases and 46.6% among all Clalit members. 63.5% of patients with GD had a Charlson Comorbidity Index (CCI) ≥1, compared with 30.4% in the general population ( Table 1 ).
• The majority of GD cases had a history of anemia (69.6%) or thrombocytopenia (62.0%). 40% had a history of a bone event and 22.2% had a history of cancer ( Table 2) . Abbreviations: ERT, enzyme replacement therapy; ERT+, the purchase of at least 1 ERT medication at any time (imiglucerase, velaglucerase alfa or taliglucerase alfa); ERT-, never treated with ERT. *Chi-square tests were used to compare group differences. † Comparison tests were not calculated for prevalence rates with low numbers and high variance. Abbreviations: CCI, Charlson Comorbidity Index; ERT, enzyme replacement therapy; ERT+, the purchase of at least 1 ERT medication at any time (imiglucerase, velaglucerase alfa or taliglucerase alfa); ERT-, never treated with ERT. Data are missing for <5% of ERT users or non-users. *Statistically significant differences between ERT groups at P<0.001.
• Crude rates of disease complications such as anemia, thrombocytopenia and hepatomegaly were more common in ERT+ than ERT-patients (P<0.02) (Figure 3) . This was expected, as those with disease manifestations were more likely to be treated. Abbreviations: ERT, enzyme replacement therapy; ERT+, the purchase of at least 1 ERT medication at any time (imiglucerase, velaglucerase alfa or taliglucerase alfa); ERT-, never treated with ERT. *Statistically significant differences between ERT groups at P<0.02.
CONCLUSIONS
• This is the first study to detail socio-economic and clinical data on a large population-based GD cohort using a comprehensive real-time EHR database. • The prevalence of GD ranged from 5.3 to 20.2 per 100,000 for patients under and over 35 years of age, respectively.
• The GD population differed socio-demographically and clinically from that of the general Clalit population.
• Statistically significant differences between those who had and had not initiated ERT treatment were observed for disease-related complications (ever), but not for pre-existing complications (ever).
• By 2014, 41.2% of all patients with GD in the Clalit EHR database had been treated with ERT.
• Monitoring such a cohort is important to understanding disease burden and outcomes in a real-world population. 
